---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-23-000063"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2023-04-17T23:59:59+00:00"
generated_at: "2026-06-17T01:25:57.581371+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Zentalis reports preclinical data linking Cyclin E1 to azenosertib sensitivity; expects clinical data in H1 2023

## Summary
- Preclinical data show azenosertib kills Cyclin E1-high tumor cells in vitro and inhibits patient-derived in vivo models.
- Data presented at AACR 2023 suggest CCNE1 amplification/Cyclin E1 expression as potential predictive marker for patient enrichment.
- Company now expects to share Phase 1b ovarian chemo combination clinical data in H1 2023, ahead of original guidance.
- Collaboration with Dr. Gordon Mills of Oregon Health & Science University on Wee1 inhibition studies.

## SEC filing metadata
- accession: 0001725160-23-000063
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2023-04-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516023000063/0001725160-23-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516023000063/zntl-20230417.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-23-000063
- JSON: https://secwatch.observer/filing/0001725160-23-000063.json
- Plain text: https://secwatch.observer/filing/0001725160-23-000063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.